Myocardial fibrosis as a risk stratifier for sudden arrhythmic death

References

• Mehra R. Global public health problem of sudden cardiac death. J. Electrocardiol.40(Suppl. 6), S118–S122 (2007).
   PubMed Web of Science ®Google Scholar
• Garfinkel A, Chen PS, Walter DO et al. Quasiperiodicity and chaos in cardiac fibrillation. J. Clin. Invest.99(2), 305–314 (1997).
   Google Scholar
• Weiss JN, Qu Z, Chen PS, Lin SF et al. The dynamics of cardiac fibrillation. Circulation112(8), 1232–1240 (2005).
   Google Scholar
• Myerburg RJ, Mitrani R, Interian A Jr, Castellanos A. Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impact. Circulation97(15), 1514–1521 (1998).
   Web of Science ®Google Scholar
• Rubart M, Zipes DP. Mechanisms of sudden cardiac death. J. Clin. Invest.115(9), 2305–2315 (2005).
   PubMed Web of Science ®Google Scholar
• Sovari AA. postinfarct cardiac remodeling and ventricular arrhythmias. In: Myocardial Ischemia; Causes, Symptoms, and Treatment. First Edition. Vukovik D, Kiyan V (Eds). Nova Science Publishers, NY, USA, 269–277 (2010).
   Google Scholar
• Sovari AA, Morita N, Weiss JN, Karagueuzian HS. Serum transforming growth factor-β1 as a risk stratifier of sudden cardiac death. Med. Hypotheses71(2), 262–265 (2008).
   PubMed Web of Science ®Google Scholar
• Brooks A, Schinde V, Bateman AC, Gallagher PJ. Interstitial fibrosis in the dilated non-ischaemic myocardium. Heart89(10), 1255–1256 (2003).
   Google Scholar
• Fielitz J, Hein S, Mitrovic V et al. Activation of the cardiac renin-angiotensin system and increased myocardial collagen expression in human aortic valve disease. J. Am. Coll. Cardiol.37(5), 1443–1449 (2001).
   PubMed Web of Science ®Google Scholar
• Wu TJ, Ong JJ, Hwang C et al. Characteristics of wave fronts during ventricular fibrillation in human hearts with dilated cardiomyopathy: role of increased fibrosis in the generation of reentry. J. Am. Coll. Cardiol.32(1), 187–196 (1998).
   Google Scholar
• Morita N, Sovari AA, Xie Y et al. Increased susceptibility of aged hearts to ventricular fibrillation during oxidative stress. Am. J. Physiol. Heart Circ. Physiol.297(5), H1594–H1605 (2009).
   PubMed Web of Science ®Google Scholar
• Sovari AA. Oxidative stress promotes ventricular fibrillation at the early stages of hypertension: role of Ca2+/CaM kinase-II. Heart Rhythm7, 5–23 (2010).
   Google Scholar
• Morita N, Lee JH, Bapat A et al. Glycolytic inhibition causes spontaneous ventricular fibrillation in aged hearts. Am. J. Physiol. Heart Circ. Physiol.301(1), H180–H191 (2011).
   PubMed Web of Science ®Google Scholar
• Miragoli M, Salvarani N, Rohr S. Myofibroblasts induce ectopic activity in cardiac tissue. Circ. Res.101(8), 755–758 (2007).
   PubMed Web of Science ®Google Scholar
• Ono N, Hayashi H, Kawase A et al. Spontaneous atrial fibrillation initiated by triggered activity near the pulmonary veins in aged rats subjected to glycolytic inhibition. Am. J. Physiol. Heart Circ. Physiol.292(1), H639–H648 (2007).
   Web of Science ®Google Scholar
• Schultz JJ, Witt SA, Glascock BJ et al. TGF-β1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J. Clin. Invest.109(6), 787–796 (2002).
   Google Scholar
• Deten A, Holzl A, Leicht M, Barth W, Zimmer HG. Changes in extracellular matrix and in transforming growth factor beta isoforms after coronary artery ligation in rats. J. Mol. Cell. Cardiol.33(6), 1191–1207 (2001).
   PubMed Web of Science ®Google Scholar
• Li G, Borger MA, Williams WG et al. Regional overexpression of insulin-like growth factor-I and transforming growth factor-β1 in the myocardium of patients with hypertrophic obstructive cardiomyopathy. J. Thorac. Cardiovasc. Surg.123(1), 89–95 (2002).
   Google Scholar
• Sanderson JE, Lai KB, Shum IO, Wei S, Chow LT. Transforming growth factor-β(1) expression in dilated cardiomyopathy. Heart86(6), 701–708 (2001).
   Google Scholar
• Mitchell JA, Ventura HO, Mehra MR. Early recognition and treatment of hypertensive heart disease. Curr. Opin. Cardiol.20(4), 282–289 (2005).
   Google Scholar
• Ban CR, Twigg SM. Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vasc. Health Risk Manage.4(3), 575–596 (2008).
   PubMedGoogle Scholar
• Ban CR, Twigg SM. Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vasc. Health Risk Manage.4(3), 575–596 (2008).
   PubMedGoogle Scholar
• Ito N, Ohishi M, Yamamoto K et al. Renin–angiotensin inhibition reverses advanced cardiac remodeling in aging spontaneously hypertensive rats. Am. J. Hypertens.20(7), 792–799 (2007).
   Google Scholar
• Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br. J. Pharmacol.133(5), 687–694 (2001).
   PubMed Web of Science ®Google Scholar
• Villarreal F, Zimmermann S, Makhsudova L et al. Modulation of cardiac remodeling by adenosine: in vitro and in vivo effects. Mol. Cell. Biochem.251(1–2), 17–26 (2003).
   PubMed Web of Science ®Google Scholar
• Maron MS. The current and emerging role of cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy. J. Cardiovasc. Transl. Res.2(4), 415–425 (2009).
   Google Scholar
• Assomull RG, Prasad SK, Lyne J et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J. Am. Coll. Cardiol.48(10), 1977–1985 (2006).
   PubMed Web of Science ®Google Scholar
• Wu KC, Weiss RG, Thiemann DR et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J. Am. Coll. Cardiol.51(25), 2414–2421 (2008).
   PubMed Web of Science ®Google Scholar
• Iles L, Pfluger H, Lefkovits L et al. Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. J. Am. Coll. Cardiol.57(7), 821–828 (2011).
   PubMed Web of Science ®Google Scholar